Core Insights - Dyadic International, Inc. reported its financial results for 2025, highlighting a strategic transition towards a commercially driven organization with a focus on expanding market access and product offerings [1][2]. Recent Company Developments and Updates - The commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals was announced, with Dyadic eligible for profit sharing from sales [5][6]. - Dyadic expanded its collaboration with Fermbox Bio, launching animal-origin-free recombinant DNase I as the first product under this partnership [5][6]. - An OEM distribution agreement was signed with IBT Bioservices to commercialize recombinant DNase I and transferrin for research and cell culture applications [5][6]. - A development and commercialization agreement with BRIG Bio was established to produce animal-free bovine alpha-lactalbumin for global nutrition markets [5][6]. - Inzymes plans to commercialize recombinant non-animal bovine chymosin in 2026 after meeting development milestones [11]. Financial Highlights - Total revenue for 2025 decreased to $3.09 million from $3.50 million in 2024, primarily due to a $638,000 reduction in research and development revenue [13]. - Grant revenue increased by $1.86 million in 2025, attributed to funding from the Gates Foundation and CEPI [13]. - The net loss for 2025 was $7.36 million, or $(0.23) per share, compared to a net loss of $5.81 million, or $(0.20) per share, in 2024 [16][25]. - Cash and cash equivalents as of December 31, 2025, were approximately $4.62 million, down from $6.51 million in 2024 [12][27]. Corporate Development - Dyadic rebranded as Dyadic Applied BioSolutions and launched a redesigned corporate website to enhance product commercialization and customer engagement [9]. - The company is expanding commercial efforts in Asia, particularly in Japan and South Korea, to facilitate market entry for its animal-free proteins [9]. - Dyadic is participating in various government- and partner-supported programs, including initiatives for vaccine development and pandemic preparedness [11].

Core Insights - Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product utilizing Dyadic's proprietary technology, marking a significant step in Dyadic's commercialization strategy [1][2][3] Company Overview - Dyadic is a global biotechnology company focused on producing precision-engineered, animal-free proteins and enzymes for various applications, including life sciences and nutrition [1][5] - Proliant is a leading global producer of purified proteins, including albumin, serving life science and diagnostic markets with a well-established distribution network [1][6] Product Launch - The launch of AlbuFree™ DX highlights Dyadic's commitment to recombinant protein products with established commercial pathways and market demand [2][3] - AlbuFree™ DX is positioned to meet the rising demand for animal-free inputs in cell culture and life science applications, representing a key milestone in Dyadic's portfolio [3][4] Strategic Partnership - Under the agreement, Dyadic will receive a share of profits from Proliant's sales of recombinant human albumin products, reinforcing the partnership's commercial viability [2][4] - Proliant's extensive experience in albumin production and distribution supports the successful integration of AlbuFree™ DX into the market [4] Future Developments - Dyadic plans to expand its portfolio of recombinant proteins for various applications through internal programs and strategic partnerships, indicating a focus on scalable commercialization [4]